Home / Encyclopedia / GLP-1 & Weight / CT-388

MONOGRAPH No. 113

EVIDENCE BASEModerate

TYPE

GLP-1 / GIP dual agonist

4825.4 g/mol

CAS

Not assigned

EU STATUS

Investigational · Not approved

WADA

Not listed

MIN PURITY

≥98% HPLC

⚖ GLP-1 & Weight

CT-388 — EU research guide.

CT-388 (also called RO7690479 or enicepatide) is Roche's investigational once-weekly dual GLP-1/GIP receptor agonist for obesity, acquired via the 2023 Carmot Therapeutics buyout.

Last reviewed: 2026-09-24

What is CT-388?

CT-388 activates both the GLP-1 and GIP receptors with minimal β-arrestin recruitment, a design intended to preserve efficacy while limiting receptor desensitisation. It's dosed by weekly subcutaneous injection, in the same mechanism class as tirzepatide.

What does the research show?

Roche's Phase 2 CT388-103 trial (469 adults with obesity, reported January 2026) showed 22.5% placebo-adjusted weight loss at 48 weeks with no plateau; over 95% of patients on the top dose lost at least 5% of body weight. Phase 3 trials ENITH-1 and ENITH-2 began in Q1 2026, alongside a planned combination study with the amylin analogue petrelintide.

EU legal status

Not approved anywhere. CT-388 is an investigational pharmaceutical owned by Roche/Genentech; it has no legitimate research-peptide supply route, and gray-market material claiming to be CT-388 cannot be authenticated.

⚠ Investigational drug in Phase 3 trials, owned by a single developer. Not EMA/FDA-approved. No human use outside authorised clinical trials.

✓ For the approved dual-agonist mechanism, PeptideCompare tracks tirzepatide from EU research vendors with COA documentation.

EVIDENCE SUMMARY

MODERATE

Weight reduction in obesity (phase 2, CT388-103) — In a 48-week, placebo-controlled phase 2 trial in 469 adults with obesity or overweight with comorbidities, the sponsor reports 22.5% placebo-adjusted weight loss at the highest dose (efficacy estimand; 18.3% with the treatment-regimen estimand), with 95.7% of participants reaching at least 5% loss. Discontinuation was 5.9% versus 1.3% with placebo. Results come from a company announcement, not yet a peer-reviewed paper.

MODERATE

Type 2 diabetes with overweight or obesity (phase 2, CT-388-104) — In a 48-week, randomised, double-blind, placebo-controlled phase 2 trial in 447 adults, the sponsor reports an HbA1c reduction of 2.65 percentage points from a baseline of 8.1% at the highest dose and a mean weight reduction of 15.5%, with mostly mild-to-moderate gastrointestinal adverse events. Two phase 3 obesity trials (ENITH-1 and ENITH-2) are described as ongoing.

Molecular information

Molecular formula

C226H345FN48O67

Molecular weight

4825.4 g/mol

CAS number

Not assigned

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

Potency retained over time

Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.

Freezer −20 °C

36+ mo

Stable · >95% potency

Fridge 4 °C

4-6 mo

In use · after recon

Room 20 °C

2-3 wks

Limited · moderate loss

Warm 37 °C+

<1 day

Critical · rapid degradation

⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.

Dual-agonist compounds across EU suppliers

COA-verified EU vendors · Updated monthly

References

Sponsor announcement of the phase 2 obesity trial (469 adults, 48 weeks). It gives topline efficacy and tolerability but no full methods, and it is a company statement rather than peer-reviewed evidence. Roche. Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity (trial CT388-103, NCT06525935). Ad hoc announcement pursuant to Art. 53 LR; 27 January 2026. Source
Sponsor announcement of the phase 2 trial in type 2 diabetes with overweight or obesity (447 adults, 48 weeks), where the compound is now called enicepatide. Again a company statement; it also says phase 3 trials for chronic weight management are ongoing. Roche. Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity (trial CT-388-104). Ad hoc announcement pursuant to Art. 53 LR; 22 September 2026. Source

CT-388 — EU research guide.

What is CT-388?

What does the research show?

EU legal status

Molecular information

Pharmacokinetics

Potency retained over time

Dual-agonist compounds across EU suppliers

References

Related guides

Tirzepatide

Retatrutide

VK2735